The epidemiology of drug-induced disorders: The kidney

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 679-690

  Taber, Stephanie S ^a   Pasko, Deborah A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acute interstitial nephritis; Acute tubular necrosis; Aminoglycosides; Amphotericin B; Ciclosporin; NSAIDs; Obstructive nephropathy; Radiocontrast dye

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPICILLIN; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; CALCINEURIN INHIBITOR; CEPHALOSPORIN DERIVATIVE; CISPLATIN; CONTRAST MEDIUM; CYCLOSPORIN; DIAMORPHINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSCARNET; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LITHIUM SALT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENICILLAMINE; PROTON PUMP INHIBITOR; RIFAMPICIN; SULFADIAZINE; SULFONAMIDE; TACROLIMUS; TRIAMTERENE; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ACUTE DISEASE; CRYSTALLURIA; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENCEPHALITIS; FLANK PAIN; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMATURIA; HEMODYNAMICS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE DAMAGE; KIDNEY TUBULE NECROSIS; LIQUID; LOW DRUG DOSE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NAUSEA; NEOPLASM; NEPHROTIC SYNDROME; NEPHROTOXICITY; PATHOGENESIS; PRESCRIPTION; PSORIASIS; PYURIA; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; VOMITING;

AMINOGLYCOSIDES; AMPHOTERICIN B; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCINEURIN; HUMANS; KIDNEY DISEASES; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; UNITED STATES;

EID: 57049098780     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802410462     Document Type: Review

References (101)

1. Choudhury D, Ahmed Z. Drug-induced nephrotoxicity. Med Clin North Am 1997;31:705-17
2. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84
3. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-6
4. Hock R, Anderson RJ. Prevention of drug-induced nephrotoxicity in the intensive care unit. J Crit Care 1995;10(1):33-43
5. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med 2003;325:349-62
6. Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin 2006;22:357-74
7. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106(5B):13S-24
8. Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002;25(7):537-44
9. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Int Med 2003;253:643-52
10. Morales E, Mucksavage JJ. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacotherapy 2002;22(10):1317-21
11. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-7
12. Saine DR, Ahrens ER. Renal impairment associated with losartan. Ann Intern Med 1996;124(8):775
13. Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 1997;1:67-76
14. Wynckel A, Ebikili B, Melin JP, et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am J Hypertens 1998;11(9):1080-6
15. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93
16. De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000;35:333-46
17. Olyaei AJ, De Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf 1999;21:471-88
18. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40
19. Burdmann EA, Andoh TF, Yu L, et al. Ciclosporin nephrotoxicity. Semin Nephrol 2003;23:465-76
20. Sica DA, Gehr TW. Triamterene and the kidney. Nephron 1989;51:454-61
21. Wright NG, Nash AS. Experimental ampicillin glomeruloneprhopathy. J Comp Pathol 1984;94:357-61
22. Baum M, Peil CF, Goodman JR. Antibiotic-associated interstitial nephritis and nephrotic syndrome. Am J Nephrol 1986;6:149-51
23. Kistler A, Lappin DW, Coward RA. Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculosis therapy with rifampicin. Nephrol Dial Transplant 1999;14:243-4
24. Kohler LJ, Gohara AF, Hamilton RW, et al. Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis. Clin Nephrol 1994;42;263-5
25. Yong JL, Killingsworth M. Diffuse glomerulonephritis associated with rifampicin treatment for tuberculosis. Pathology 2002;34:295-7
26. Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000;11:1439-48
27. Neithercut WD, Spooner RJ, Hendry A, et al. Persistent nephrogenic diabetes insipidus, tubular proteinuria, aminoaciduria, and parathyroid hormone resistance following longterm lithium administration. Postgrad Med J 1990;66:479-82
28. Santella RN, Rimmer JM, MacPherson BR. Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am J Med 1988;84:951-4
29. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72
30. Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol 1997;8:664-74
31. Almroth G, Enestrom S, Hed J, et al. Autoantibodies to leucocyte antigens in hydralazine associated nephritis. J Intern Med 1992;231:37-42
32. Ihle BU, Whitworth JA, Dowling JP, et al. Hydralazine and lupus nephritis. Clin Nephrol 1984;22:230-8
33. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular disease. Kidney Int 2002;61:1098-114
34. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999;70:S26-32
35. Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998;9:1333-40
36. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994;23:773-83
37. Mingeot Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43(5):1003-12
38. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997;17:27-33
39. Humes HD, Weinberg JM, Krauss TC. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 1982;2:5-29
40. Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 2001;13(5):461-72
41. Nagai J, Takan M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004;19(3):159-70
42. Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004;32(8):1678-82
43. Cronin R, Nix K, Ferguson E, et al. Renal cortex ion composition and Na-K-ATPase activity in gentamicin nephrotoxicity. Am J Physiol 1982;242:F477-83
44. Schardijn GC, Statius van Eps LW. B-2 microglobulins: its significance in the evaluation of renal function. Kidney Int 1987;32:635-41
45. Joannidis M. Drug-induced renal failure in the ICU. Int J Artif Org 2004;27(12):1034-42
46. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc 1998;73:1205-25
47. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(Suppl S1):37-41
48. Tiphine M, Letscher Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999;1:273-83
49. Berdichevski RH, Luis LB, Crestana L, et al. Amphotericin B-related nephrotoxicity in low-risk patients. Braz J Infect Dis 2006;10:94-9
50. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22(2):315-21
51. Walsh TJ, Finberg RT, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340(10):764-71
52. White MH, Bowden RA, Sandler RA, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302
53. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventative strategies. CMAJ 2005;172(11):1461-71
54. Rudnick MR, Berns JS, Cohen RM, et al. Contrast media-associated nephrotoxicity. Semin Nephrol 1997;17:54-66
55. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 1998;53:230-42
56. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;68:14-22
57. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15(1):18-22
58. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103(5):368-75
59. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105(19):2259-64
60. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188(1):171-8
61. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-34
62. Goldenberg I, Schechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004;25(3):212-8
63. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Int Med 2008;148:284-94
64. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-82
65. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4
66. Berns JS, Ford PA. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin Nephrol 1997;17:54-66
67. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38
68. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 1992;50:147-58
69. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005;351:31-47
70. Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol 1998;9(3):506-15
71. Sakarcan A, Marcille R, Stallworth J. Antibiotic-induced recurring interstitial nephritis. Pediatr Nephrol 2002;17:50-1
72. Toto RD. Review: acute tubulointerstitial nephritis. Am J Med Sci 1990;299(6):392-410
73. Wai AO, Lo A, Abdo A, et al. Vancomycin-induced acute interstitial nephritis. Ann Pharmacother 1998;32:1160-64
74. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001;60:804-17
75. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology 2006;11:381-5
76. Harmark L, Van der Wiel HE, De Groot MC, Van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 2007;64:819-23
77. Sierra F, Suarez M, Rey M, Velas MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007;26:545-53
78. Griffin MD, Bergstralhn EJ, Larson TS. Renal papillary necrosis - a sixteen-year clinical experience. J Am Soc Nephrol 1995;6:248-56
79. Bennett WM, DeBroe ME. Analgesic nephropathy - a preventable renal disease. N Engl J Med 1989;320:1269-71
80. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998;338:446-52
81. Elseviers MM, De Brow ME. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use? Drug Saf 1999;20:15-24
82. Izzedine H, Launay Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005;45(5):804-17
83. Perazella MA. Crystal-induced acute renal failure. Am J Med 1999;106:459-65
84. Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985;151(2):362-5
85. Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982;73:182-5
86. Keeney RE, Kirk LE, Bridgen D. Acyclovir tolerance in humans. Am J Med 1982;73:176-81
87. Krasny HC, Liao SH, De Miranda P, et al. Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am J Med 1982;73(1A):202-4
88. Laskin OL, Longstreth JA, Whelton A, et al. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 1982;73(1A):197-201
89. Simon DI, Brosius FC, Rothstein DM. Sulfadiazine crystalluria revisited. Arch Intern Med 1990;150:2379-84
90. Becker K, Jablonowski H, Haussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine 1996;75:185-94
91. Hein R, Brunkhorst R, Thon WF, et al. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993;39:254-6
92. Walls M, Goral S, Stone W. Acute renal failure due to sulfinpyrazone. Am J Med Sci 1998;315:319-21
93. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11:694-703
94. Maurice Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998;32:392-400
95. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25
96. Filler G, Foster J, Acker A, et al. The Cockcroft-Gault formula should not be used in children. Kidney Int 2005;67:2321-24
97. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockcroft-Gault, Jellife, and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291-5
98. Supakevin S, Zhang W, Kucherlapati R, et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003;63:1714-24
99. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008;148:810-9
100. Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007;22:2089-95
101. Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007;156:203-12